logo-loader
viewDyadic International Inc

Full interview: Dyadic paves the way for patients to gain access to low-cost SARS-COV2 and other vaccines and drugs

Dyadic (NASDAQ) President and CEO Mark Emalfarb joined Steve Darling from Proactive Vancouver with news the company continues to very busy even with the COVID-19 crisis. Emalfarb discussing what the company is doing with other partners to help battle the virus. 

Emalfarb also telling Proactive about a deal they signed with a major biological company WuXi.

Quick facts: Dyadic International Inc

Price: 8.38 USD

NASDAQ:DYAI
Market: NASDAQ
Market Cap: $230.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Dyadic touts recent collaborations, 3Q highlights at Jefferies London...

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb and CCO Matthew Jones tell Proactive's Andrew Scott the duo are in London for the Jefferies London Healthcare Conference, the biotech's third year attending.  Emalfarb and Jones say the Florida-based biotech is touting its recent...

on 18/11/19

2 min read